ESMO Open | |
How I treat MALT lymphoma: ‘a subjective interpretation of the gospel according to Isaacson….’ | |
article | |
Markus Raderer1  Barbara Kiesewetter1  | |
[1] Department of Medicine I, Division of Oncology, Medical University of Vienna | |
关键词: MALT lymphoma; extranodal lymphoma; Helicobacter pylori; antibiotics; chemotherapy; | |
DOI : 10.1136/esmoopen-2020-000812 | |
学科分类:社会科学、人文和艺术(综合) | |
来源: BMJ Publishing Group | |
【 摘 要 】
Mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) is an indolent B-cell lymphoma characterised by a fascinating interplay between chronic antigenic stimulation, an immune response insufficient for elimination of the antigen and a mucosal ‘battleground’. The archetype of this association is infection of the gastric mucosa with Helicobacter pylori (HP): a single course of antibiotic HP-eradication treatment may result in long-term remission in up to 80% of patients and is the gold standard for first-line therapy of HP-associated gastric MALT lymphoma. In extragastric or disseminated disease, treatment options range from wait and see in asymptomatic individuals to radiotherapy in localised stages, anti-CD20-antibodies in patients with low symptomatic burden and chemotherapy-based treatment or radio-immunotherapy in symptomatic disease. In addition, more refined immunomodulatory strategies beyond simple eradication of bacteria such as long-term use of the macrolide clarithromycin or the immunomodulatory drug lenalidomide are active. In view of the indolent clinical course, the least toxic individual treatment should be chosen in a disease usually not influencing overall survival in affected patients.
【 授权许可】
CC BY|CC BY-NC-ND
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202303290004722ZK.pdf | 341KB | download |